Resonance Health Limited (ASX:RHT)

Dr Blake is a Radiologist and Nuclear Medicine Specialist and brings a wealth of technical and industry experience to Resonance Health. He is a Fellow of the Australian Institute of Company Directors, holding directorships on several private and public company boards and was chairman of Perth Radiological Clinic from 2009-21. Dr Blake is a business development professional graduated from the University of Melbourne – Melbourne Business School, is a practicing radiologist, has over 20 years of experience and insight into healthcare M&A, and brings skills in innovation and technology commercialisation.

Mitchell is an experienced senior executive and a qualified lawyer with commercial and legal experience in Australia, the United States and the United Kingdom. He has served as a director and worked as a senior executive of listed public and private companies including ASX and Nasdaq listed companies. He has international management experience in several industries, including as project manager and lawyer for AEG Europe and The O2 in London, UK. Prior to that, he was legal counsel for London 2012 which successfully bid to host the 2012 Olympic Games. He holds Bachelor degrees in Law and Commerce and a Diploma of Aviation. He joined Resonance Health in 2017 as legal consultant. He has served as Chair of two not-for-profit organisations.

Simon has been a major shareholder of Resonance Health since 2008 and joined the board in 2009, as he is a strong believer in liver health technologies. He started and ran his own successful small business for over 15 years and brings skills in business and marketing. He has experience in the property industry, financial markets, and the acquisition and disposal of investments. He currently manages assets and projects associated within family holdings and was a previous Non-Executive Director of 4DS Ltd.

Travis has broad experience across different sectors: industrial research, commercialisation of technology, asset valuations, and investment banking services. He has been a manager of innovation development and technology strategy in a large company setting, as well as an active investor in early-stage investments. He has worked in investment banking, providing advisory services to equity capital market transactions, corporate research, and valuations to clients.

Aaron had a 22-year career with Gilead Sciences, Inc. (Nasdaq: GILD) (Gilead) during which time the company grew from a small biotech-pharma company to a multi-billion-dollar global company with annual sales of over USD $27 billion. He held several commercial, licensing, and patient access roles at Gilead, including that of Executive Director – Global Patient Solutions, where he was responsible for commercial and access strategies for emerging markets. He led Gilead’s commercial and access operations in the Asia Pacific (APAC) where he managed a geographically dispersed team and partners across 31 APAC countries including China, India, and Vietnam. He completed their Snr Leadership Development Program and was recognised with multiple awards. He has a Bachelor’s degree in Health Sciences from Edith Cowan University, and has served on the Board of the Royal Surf Lifesaving Society of Western Australia since 2020. He is a graduate of the AICD Company Directors course and maintains active membership of the AICD.